India, a proactive player in this high-stakes narrative, has rejected this application, employing a robust set of domestic intellectual property laws. Section 3D of the Indian Patent Act is a crucial weapon in the country’s arsenal, designed to thwart pharmaceutical giants’ “evergreening” tactics.